<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489733</url>
  </required_header>
  <id_info>
    <org_study_id>508917</org_study_id>
    <nct_id>NCT03489733</nct_id>
  </id_info>
  <brief_title>Prevention of Allergic Diseases in Infants</brief_title>
  <official_title>The Effect of Low Protein, Extensively Hydrolyzed Infant Formula on Allergy Prevention in At-risk Infants up to 1 Year of Age: a Randomized, Double-blind, Controlled Intervention Study and the Long-term Effect on Allergy Prevention of Early Nutrition Given in the First 120 Days of Life in At-risk Infants Until the Child is 6 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HiPP GmbH &amp; Co. Vertrieb KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HiPP GmbH &amp; Co. Vertrieb KG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, prospective, randomized, controlled, doubleblind intervention clinical Trial
      is performed to proof the efficiency of hydrolyzed infant formula showing a risk reduction of
      developing an allergy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of atopic dermatitis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1170</enrollment>
  <condition>Atopic Diseases</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Fed Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hydrolyzed Formula</intervention_name>
    <description>Infant formula with extensively hydrolyzed proteins and pre- and probiotics.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control formula</intervention_name>
    <description>Infant formula with intact proteins and pre- and probiotics.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy term-born male and female infants (gestational Age ≥37+0, twins allowed)

          -  Birth weight ≥ 2500 g and ≤ 4500 g

          -  Age at enrollment: ≤ 28 days of life

          -  At risk of developing atopic diseases

          -  Free of atopy symptoms at Screening and at any time before randomization

          -  Feeding regimen at any time before Screening (V1) and Baseline (V2, infants who will
             receive Interventional Product (IP)): no infant formula feeding and solid foods
             allowed (in order to exclude prior sensitization) except amino acid formula (e.g.
             Neocate Infant), maltodextrin or glucose solution/gel; breastfeeding allowed

          -  Subject's parents/caregivers willing to comply with the feeding regimen during the
             intervention period. Subject's parents/caregivers will decide which feeding regimen
             will be used (IP or breast milk):

               -  IP regimen (intervention or control group): only IP and breast milk until at
                  least 120 days of life

               -  breastfeeding regimen (reference group): exclusively breast milk until at least
                  120 days of life.

               -  No other infant formulas or solid foods are allowed.

          -  Written informed consent.

        Exclusion Criteria:

          -  Triplets or quadruplets

          -  Premature delivery (gestational age ≤ 36+6)

          -  Neonatal illnesses that might have an impact on allergy development (based on
             Investigator's decision)

          -  Significant congenital abnormalities

          -  Participation in another clinical study with an IP or study method that would
             influence the outcome of this study

          -  Reason to presume that the subject's parents/caregivers are unable to meet study plan
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Beyer, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bianca Arendt, Dr.</last_name>
    <phone>+4984417571047</phone>
    <email>Bianca.Arendt@hipp.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second specialized obstetric and gynecological hospital for active treatment Sheinovo EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Strakonice, a.s.</name>
      <address>
        <city>Strakonice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suomen Terveystalo Oy</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin der Ruhruniversität Bochum im St. Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Studienambulanz der pädiatrische Pneumologie und AllergologieKlinik für Kinder- und Jugendmedizin (KKJM)</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder und Jugendmedizin</name>
      <address>
        <city>Hamm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinder und Jugendkrankenhaus Auf der Bult</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin Marienhospital gGmbH Wesel</name>
      <address>
        <city>Wesel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unità Allergologia-Unità Allergologia-</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Mikroekologii</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital braga</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center &quot;Dr Dragisa Misovic-Dedinje&quot;</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

